Skip to content
Upcoming events
AEEDC Dubai 202719–21 January 2027World Health Expo (WHX) Dubai 202725–28 January 2027ChinaDental South China 20273–6 March 2027GermanyIDS 2027 — International Dental Show16–20 March 2027United StatesAAD Annual Meeting 202719–23 March 2027Dubai Derma 20276–8 April 2027Dental-Expo Moscow Spring 202726–29 April 2027France7th World Congress of Dermoscopy12–15 May 2027GermanyEADV Symposium 202720–22 May 2027United StatesASCO Annual Meeting 20274–8 June 2027ChinaSino-Dental 20279–12 June 2027White Nights 2027 — St. Petersburg International Oncology ForumUsually early JulyArmenian Medical World Congress 20278–10 July 2027Dental-Expo Moscow 2027Usually late SeptemberNetherlandsEADV Congress 202722–25 September 2027SpainEAO Congress 202723–25 September 2027CanadaCFAS Annual Meeting 202723–25 September 2027Russian Health Care Week 2027Usually December
Internal Medicine

FDA grants RMAT designation to nula-cel, a gene-corrected stem cell therapy for sickle cell disease

Microscopic image showcasing the intricate structure and texture of plant cells.

Key facts

  • The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to nula-cel, an investigational therapy for sickle cell disease.
  • Nula-cel uses the patient’s own blood stem cells, in which the sickle mutation is corrected to the normal adult beta-globin sequence.
  • The designation is based on preliminary data from the Phase 1/2 RESTORE trial; the therapy is not yet approved.

What happened

The U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nula-cel, an investigational stem cell therapy for sickle cell disease developed by Kamau Therapeutics. The designation was based on preliminary clinical evidence from the Phase 1/2 RESTORE trial. Nula-cel already holds Fast Track and Orphan Drug designations.

Unlike approaches that switch on fetal haemoglobin to compensate for the disease, nula-cel is designed to correct the sickle mutation itself in the patient’s own blood-forming stem cells, converting it to the normal adult beta-globin sequence. The corrected cells are then returned to the patient.

Why it matters

Sickle cell disease is an inherited blood disorder that causes painful crises, anaemia, organ damage and a shorter life expectancy. It affects millions of people worldwide, especially in Africa, the Middle East, India and among people of African descent. Gene-based therapies offer the possibility of a one-time treatment, and a therapy that repairs the mutation directly could, in principle, restore normal haemoglobin production.

Context

RMAT designation does not mean the therapy works or is approved. It gives the company more frequent interaction with the FDA and can speed up development if results hold. The information comes from a company announcement, and full trial data have not yet been published in a peer-reviewed journal. Like other gene therapies, treatment requires stem cell collection and chemotherapy conditioning, which carry risks, and access and cost remain major challenges.

What it means for clinicians and students

  • Clinicians: patients and families will ask about gene therapy; explain the difference between approved options and investigational ones, and refer to specialist centres for trial eligibility.
  • Dental and surgical teams: people with sickle cell disease need careful planning for procedures, including hydration, infection prevention and pain management.
  • Students: compare gene correction with gene addition and fetal haemoglobin induction — a frequent exam topic in haematology and genetics.

Source: Kamau Therapeutics (company release via GlobeNewswire)